please talk to your doctor and see the full Prescribing Information for EYLEA HD and EYLEA. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes ...

Approval for Eylea for diabetic retinopathy was based on six-month and one-year trial results from PANORAMA, a phase 3 trial that enrolled 402 patients comparing the drug with placebo.

and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...